Detalles de la búsqueda
1.
Post hoc analysis of daratumumab plus lenalidomide, bortezomib and dexamethasone in Black patients from final data of the GRIFFIN study.
Br J Haematol
; 2024 Mar 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-38504552
2.
Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE.
Blood
; 139(4): 492-501, 2022 01 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-34269818
3.
Health-related quality of life in transplant-eligible patients with newly diagnosed multiple myeloma treated with daratumumab, lenalidomide, bortezomib, and dexamethasone: Patient-reported outcomes from GRIFFIN.
Am J Hematol
; 2024 Apr 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-38622840
4.
Switching to daratumumab SC from IV is safe and preferred by patients with multiple myeloma.
J Oncol Pharm Pract
; 29(5): 1172-1177, 2023 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-36067063
5.
Daratumumab plus lenalidomide, bortezomib and dexamethasone in newly diagnosed multiple myeloma: Analysis of vascular thrombotic events in the GRIFFIN study.
Br J Haematol
; 199(3): 355-365, 2022 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-36111391
6.
Daratumumab Improves Depth of Response and Progression-free Survival in Transplant-ineligible, High-risk, Newly Diagnosed Multiple Myeloma.
Oncologist
; 27(7): e589-e596, 2022 07 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-35462406
7.
Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial.
Blood
; 136(8): 936-945, 2020 08 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-32325490
8.
A plain language summary of daratumumab plus lenalidomide/bortezomib/dexamethasone in transplant-eligible Black patients with newly diagnosed multiple myeloma in the GRIFFIN study.
Future Oncol
; 18(40): 4443-4456, 2022 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-36799429
9.
Daratumumab for patients with myeloma with early or late relapse after initial therapy: subgroup analysis of CASTOR and POLLUX.
Blood Adv
; 8(2): 388-398, 2024 01 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-38048391
10.
Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic risk.
Blood Cancer J
; 14(1): 69, 2024 Apr 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-38649340
11.
Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial.
Lancet
; 379(9825): 1489-97, 2012 Apr 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-22521071
12.
Impact of cytogenetic abnormalities on treatment outcomes in patients with amyloid light-chain amyloidosis: subanalyses from the ANDROMEDA study.
Amyloid
; 30(3): 268-278, 2023 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-36779691
13.
Stem Cell Mobilization Yields with Daratumumab- and Lenalidomide-Containing Quadruplet Induction Therapy in Newly Diagnosed Multiple Myeloma: Findings from the MASTER and GRIFFIN Trials.
Transplant Cell Ther
; 29(3): 174.e1-174.e10, 2023 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36494017
14.
Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial.
Lancet Haematol
; 10(10): e825-e837, 2023 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-37708911
15.
Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA.
Leukemia
; 36(4): 1066-1077, 2022 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-34974527
16.
Clinical Utility of Wearable Sensors and Patient-Reported Surveys in Patients With Schizophrenia: Noninterventional, Observational Study.
JMIR Ment Health
; 8(8): e26234, 2021 Aug 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-34383682
17.
Daratumumab Monotherapy for Relapsed or Refractory Multiple Myeloma: Results of an Early Access Treatment Protocol in Europe and Russia.
Oncol Ther
; 9(1): 139-151, 2021 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-33630275
18.
Daratumumab plus RVd for newly diagnosed multiple myeloma: final analysis of the safety run-in cohort of GRIFFIN.
Blood Adv
; 5(4): 1092-1096, 2021 02 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-33606004
19.
Results of the daratumumab monotherapy early access treatment protocol in patients from Brazil with relapsed or refractory multiple myeloma.
Hematol Transfus Cell Ther
; 43(4): 417-423, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-32967807
20.
Greater treatment satisfaction in patients receiving daratumumab subcutaneous vs. intravenous for relapsed or refractory multiple myeloma: COLUMBA clinical trial results.
J Cancer Res Clin Oncol
; 147(2): 619-631, 2021 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-32852632